TLDR

  • Veeva’s stock rose approximately 12% following a Q4 earnings beat, reporting adjusted EPS of $2.06 compared to the expected $1.94.
  • Revenue reached $836 million, marking a 16% year-over-year increase and surpassing the $811 million forecast.
  • The company’s Q1 guidance—EPS between $2.13 and $2.14, and revenue ranging from $855 million to $858 million—exceeded Wall Street’s projections.
  • For fiscal year 2027, Veeva projects revenue of $3.585 billion to $3.6 billion, which is higher than the $3.56 billion consensus estimate.
  • Ten out of the top 20 biopharmaceutical firms have pledged to use Veeva’s Vault CRM platform.

Veeva Systems got off to a rocky start in 2026, with its stock dropping 16% leading up to its earnings report. But Wednesday night turned things around.

Veeva’s Q4 performance far exceeded analysts’ expectations. Adjusted EPS hit $2.06, beating the consensus of $1.94. Revenue climbed 16% year-over-year to $836 million, surpassing the $811 million forecast.

The market reacted promptly: VEEV shares jumped about 12% in early Thursday trading.

VEEV Stock Card

The positive results weren’t limited to the previous quarter—Veeva’s forward guidance also provided investors with a reason to stay optimistic.

For Q1, Veeva expects EPS to range from $2.13 to $2.14, which is above the $2.10 Wall Street forecast. Its revenue guidance of $855 million to $858 million also beat the $853 million estimate.

For fiscal year 2027, the company forecasts revenue between $3.585 billion and $3.6 billion—exceeding the $3.56 billion consensus. Its non-GAAP EPS guidance of $8.85 also outpaced the expected $8.60.

Analysts paid special attention to the billings guidance. KeyBanc’s Scott Schoenhaus pointed out that the “healthy billings guidance” helped bolster the company’s valuation amid a period of significant selling pressure on software stocks.

Schoenhaus, who assigns a Sector Weight rating to VEEV, stated that the results should alleviate worries about the wider software sector selloff linked to new AI coding tools.

The CRM Commitment

A notable detail from the report was that Veeva announced 10 of the top 20 biopharmaceutical companies have now committed to its Vault CRM platform.

This is a tangible indication of momentum in one of Veeva’s key product lines.

Vault CRM is tailored for life sciences firms, managing regulatory and operational workflows that generic CRM tools don’t address effectively. Gaining the trust of major pharmaceutical companies takes time, so these commitments are significant.

Veeva’s financial metrics support its growth narrative. The company has a net margin of 27.93% and a gross margin of 75.67%. Its current ratio is 7.53, and its debt-to-equity ratio is a mere 0.01.

By any standard, this is a strong and healthy balance sheet.

Valuation Check

Prior to the earnings-driven rally, VEEV’s P/E ratio of 36.67 was close to its 10-year low. Its P/S ratio of 10.25 and P/B ratio of 4.4 were also near multi-year lows.

Analysts’ consensus target price for VEEV was $292.17, which was significantly higher than the stock’s pre-earnings trading price.

Institutional investors own 86.51% of VEEV, indicating widespread confidence from large funds. Insider ownership is lower at 7.59%, and insiders sold 1,000 shares over the past three months.

Veeva’s three-year revenue growth rate is 13.4%, and its Altman Z-Score of 19.88 signals robust financial stability.

As of early Thursday, VEEV was trading at approximately $201.33, up from around $188 prior to the earnings announcement.